GSP301 Nasal Spray Improves QoL in Seasonal Allergic Rhinitis
Patients who received a fixed-dose combination nasal spray showed significantly improved Physician-assessed Nasal Symptom Scores compared with those who received placebo.
Patients who received a fixed-dose combination nasal spray showed significantly improved Physician-assessed Nasal Symptom Scores compared with those who received placebo.
Adverse drug reactions from the 300IR 5-grass pollen tablet occurred in approximately half of patients but typically resolved within a week of treatment.
Montelukast plus levocetirizine demonstrated a significant reduction in mean daytime nasal symptom scores compared with montelukast monotherapy.
According to the report, the patient complained of a non-productive cough, accumulation of mucus, and post-nasal drip and requested a thorough assessment of her medical conditions.
The NDA included safety and efficacy data from 2 randomized, multicenter, double-blind, placebo-controlled trials in patients aged ≥12 years with seasonal allergic rhinitis (N=2352).
The recalled nasal decongestant has a Lot number of 173089J and an expiration date of 09/19; it is packaged in 0.5 fluid ounce bottles.
The researchers found that the budesonide group had a mean score on the Sino-Nasal Outcome Test (SNOT-22) that was 7 points better (95% confidence interval, −2 to 16) than the control group.
Because determining an appropriate treatment plan for a patient depends on the subtype of the disease, it is imperative for providers to know and understand the underlying mechanisms of CRS as well as the components included in a medical evaluation of a patient.
Fluticasone Propionate Nasal Spray is a corticosteroid indicated for the management of the nasal symptoms of perennial nonallergic rhinitis in adults and pediatric patients aged 4 years and older.
A total of 27 articles were identified. Of these, 6 evaluated symptoms, 9 assessed QOL, 5 studied daily activities, 3 evaluated emotional aspects, 6 assessed sleep, 7 studied education, and 2 evaluated treatment burden.